ClinicaliQ Trial Snapshot
- Investigation of Cardioversion Versus Therapeutic Ablation for Persistent AF (ORBICA-AF) — Recruiting • Non-phase study • Cardiology / Cardiovascular • NCT06096246.
- What is being tested: Catheter ablation with pulmonary vein isolation compared to DC cardioversion alone in patients with persistent atrial fibrillation, measuring AF recurrence rates as the primary outcome.
- Patient eligibility overview: Adults with persistent atrial fibrillation (typically those who have failed or are unsuitable for antiarrhythmic drug therapy) who require rhythm control intervention are eligible for randomisation to either ablation or cardioversion treatment strategies.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The main aim of the research is to investigate whether patients undergoing pulmonary vein isolation with catheter ablation for persistent atrial fibrillation (AF) will have lower rates of AF recurrence than those treated by DC cardioversion without an ablation procedure.
Eligibility Snapshot
- : * Ability to give informed consent * Age 18-85 years * Persistent AF (atrial fibrillation lasting > 7days) of total continuous duration 40 * Patients in Persistent AF who have had more than one previous cardioversion. * Established diagnosis of Hypertrophic cardiomyopathy
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.